US stock · Healthcare sector · Drug Manufacturers—General
B
Bristol-Myers Squibb Company
BMY
NYSE65.94
USD
+0.28
(+0.43%)
Market Open
18.85P/E
8Forward P/E
0.77P/E to S&P500
138.530BMarket CAP
3.38%Div Yield
Upcoming Earnings
27 Jul
Shares Short
5/15/23
21.49M
Short % of Float
1.02%
Short % of Shares Outs.
1.02%
% Held by Insiders
0.07%
% Held by Institutions
78.62%
Beta
0.43
PEG Ratio
2.18
52w. high/low
81.44/63.07
Avg. Daily Volume
8.17M
Return %
Stock
S&P 500
1 year
(12.23)
3.92
3 years
8.62
37.71
5 years
28.27
56.01
Scale: |
High
Low
27.37
16.00
26.62
17.23
28.00
22.24
35.44
24.97
36.34
30.64
54.49
32.50
61.77
46.30
70.87
51.82
77.12
49.03
66.10
46.01
70.05
46.94
64.75
42.48
68.34
45.76
69.75
53.22
81.44
60.86
75.18
63.07
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
9.82
10.42
9.53
11.37
12.50
10.55
9.97
9.58
9.93
11.63
12.63
13.82
15.33
18.83
21.54
21.44
21.64
Earnings per share
1.10
2.65
5.38
1.81
2.18
1.17
1.56
1.21
0.94
2.67
0.61
3.01
2.02
(3.99)
3.25
2.94
3.46
FCF per share
1.17
1.40
1.69
2.37
2.63
3.83
1.83
1.58
0.61
0.98
2.57
3.06
4.24
5.89
7.08
5.55
5.23
Dividends per share
1.12
1.24
1.26
1.29
1.33
1.37
1.40
1.45
1.49
1.52
1.57
1.60
1.57
1.80
2.04
2.15
2.19
CAPEX per share
0.43
0.48
0.37
0.25
0.22
0.33
0.33
0.32
0.49
0.73
0.64
0.58
0.49
0.33
0.45
0.52
0.54
Book Value per sh.
5.36
6.19
7.52
9.17
9.39
8.16
9.22
8.96
8.56
9.68
7.14
8.59
30.26
16.75
16.70
14.43
15.13
Comm.Shares outs.
1,970
1,977
1,974
1,713
1,700
1,670
1,644
1,657
1,667
1,671
1,645
1,633
1,705
2,258
2,153
2,153
2,118
Avg. annual P/E ratio
26.1
8.1
4.0
14.1
13.2
28.5
28.2
43.3
68.3
23.8
93.6
19.1
24.9
(15.1)
19.4
24.7
18.9
P/E to S&P500
1.5
0.4
0.1
0.7
0.8
1.9
1.7
2.4
3.4
1.1
4.0
0.8
1.0
(0.4)
0.6
1.2
0.8
Avg. annual div. yield
3.9%
5.8%
5.8%
5.0%
4.6%
4.1%
3.2%
2.8%
2.3%
2.4%
2.7%
2.8%
3.1%
3.0%
3.2%
3.0%
3.1%
Revenue (m)
19,348
20,597
18,808
19,484
21,244
17,621
16,385
15,879
16,560
19,427
20,776
22,561
26,145
42,518
46,385
46,159
45,848
Operating margin
18.2%
20.6%
30.5%
29.1%
31.3%
22.3%
17.9%
10.8%
10.4%
23.4%
16.6%
22.7%
22.6%
5.1%
15.9%
19.7%
23.4%
Depreciation (m)
892
816
707
744
801
681
763
467
376
382
789
637
1,746
10,380
10,686
9,595
9,770
Net profit (m)
2,165
5,247
10,612
3,102
3,709
1,960
2,563
2,004
1,565
4,457
1,007
4,920
3,439
(9,015)
6,994
6,327
7,311
Income tax rate
22.7%
24.1%
21.1%
25.7%
24.7%
(6.9)%
10.8%
14.8%
21.5%
23.8%
81.0%
17.1%
30.5%
(30.9)%
13.4%
17.7%
15.9%
Net profit margin
11.2%
25.5%
56.4%
15.9%
17.5%
11.1%
15.6%
12.6%
9.5%
22.9%
4.8%
21.8%
13.2%
(21.2)%
15.1%
13.7%
16.0%
Working capital (m)
1,704
8,053
7,645
6,534
7,538
1,242
6,476
6,147
2,398
4,863
5,291
6,506
11,050
11,112
11,394
5,383
8,001
Long-term debt (m)
4,381
6,585
6,130
5,328
5,376
6,568
7,981
7,242
6,550
5,716
6,975
5,646
44,059
49,169
40,479
35,056
36,448
Equity (m)
10,562
12,241
14,843
15,713
15,956
13,623
15,154
14,852
14,266
16,177
11,741
14,031
51,598
37,822
35,946
31,061
31,824
ROIC
13.1%
21.8%
38.2%
14.6%
16.6%
7.7%
10.5%
8.7%
7.3%
18.6%
4.3%
20.9%
3.5%
(7.2)%
9.3%
9.8%
12.0%
Return on capital
11.3%
22.2%
38.6%
15.4%
16.9%
5.5%
8.0%
7.6%
6.9%
18.0%
16.0%
17.6%
4.3%
(4.6)%
8.6%
9.2%
11.4%
Return on equity
20.5%
42.9%
71.5%
19.7%
23.2%
14.4%
16.9%
13.5%
11.0%
27.6%
8.6%
35.1%
6.7%
(23.8)%
19.5%
20.4%
23.0%
Plowback ratio
(2.2)%
53.1%
79.1%
51.2%
57.1%
8.6%
10.5%
(18.2)%
(51.9)%
43.5%
(164.3)%
47.2%
22.6%
145.3%
37.3%
27.0%
36.6%
Div.&Repurch./FCF
81.4%
88.8%
49.7%
62.1%
64.3%
66.1%
72.4%
80.5%
218.5%
158.8%
119.6%
58.8%
138.0%
- -
70.1%
105.7%
71.3%
Capital Structure
27 Apr · 2023 | Q1
All numbers in millions
Total liabilities
$ 62,395
Total assets
$ 94,281
Long-term debt
$ 36,448
Cash and equiv.
$ 8,995
Goodwill
$ 21,162
Retained earnings
$ 26,568
Common stock
2,099
Enterprise Value
$ 165,983
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
16,450
17,221
9,253
Receivables
8,501
12,516
9,886
Inventory
2,074
2,095
2,339
Other
3,167
863
372
Current assets
30,192
33,262
27,273
Acc. Payable
2,713
2,949
3,040
Debt due
2,504
5,117
4,264
Other
13,863
13,802
14,586
Current liabilities
19,080
21,868
21,890
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(0.49)%
21.78%
13.46%
Cash flow
(21.57)%
30.46%
31.72%
Earnings
(9.54)%
(144.84)%
(14.12)%
Dividends
5.41%
16.98%
8.94%
Book value
(13.59)%
55.62%
24.67%
Insider Trading
Type
Shares
Date
Vessey Rupert
Sale
50,385
05/03/23
Lenkowsky Adam
Award
5,494
05/01/23
Lenkowsky Adam
Award
8,241
05/01/23
Greenlees Sharon
Exempt
689
05/02/23
Greenlees Sharon
Other
62
05/02/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
11,073
11,703
11,624
11,985
46,385
2022
11,648
11,887
11,218
11,406
46,159
2023
11,337
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.94
0.49
0.72
1.10
3.25
2022
0.59
0.66
0.75
0.94
2.94
2023
1.08
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.51
0.51
0.51
0.51
2.04
2022
0.55
0.53
0.54
0.53
2.15
2023
0.57
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Dr. Giovanni Caforio M.D.
Full-time employees:
34,300
City:
New York
Address:
430 East 29th Street
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Recent News
· 26 Apr, 2023 · The Wall Street Journal
· 26 Jul, 2022 · The Wall Street Journal
· 3 Jun, 2022 · The Wall Street Journal
· 29 Apr, 2022 · The Wall Street Journal